MedTrace Logo

Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

NCT00977665 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2015-02-26

Study results available
· View outcomes & findings →

Summary

To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.

Conditions

Interventions

DRUG

rasagiline mesylate

rasagiline 1 mg tablet/day for 48 weeks

DRUG

placebo

placebo tablet for 48 weeks

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Werner Poewe, Prof · Innsbruck Medical University, Innsbruck, Austria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States
  • Austria
  • Canada
  • France
  • Germany
  • Hungary
  • Israel
  • Italy
  • Netherlands
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00977665 on ClinicalTrials.gov